Homogeneous and digital proximity ligation assays for the detection of Clostridium difficile toxins A and B by Dhillon, Harvinder S. et al.
RH
o
H
D
a
b
c
a
A
R
R
A
A
H
K
P
M
D
C
q
d
1
a
a
a
p
s
c
c
a
l
h
2
4Biomolecular Detection and Quantiﬁcation 10 (2016) 2–8
Contents lists available at ScienceDirect
Biomolecular  Detection  and  Quantiﬁcation
jo ur nal ho me pa ge: www.elsev ier .com/ locate /bdq
esearch  paper
omogeneous  and  digital  proximity  ligation  assays  for  the  detection
f  Clostridium  difﬁcile  toxins  A  and  B
arvinder  S.  Dhillona,  Gemma  Johnsona, Mark  Shannonb, Christina  Greenwooda,
oug  Robertsc, Stephen  Bustina,∗
Postgraduate Medical Institute, Faculty of Medical Science, Anglia Ruskin University, Chelmsford, Essex, UK
Thermo Fisher Scientiﬁc, South San Francisco, CA, USA
Exosome Diagnostics, Cambridge, MA, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 20 April 2016
eceived in revised form 22 June 2016
ccepted 27 June 2016
vailable online 31 August 2016
andled by: Jim Huggett
eywords:
roximity ligation assay
onoclonal antibody
iagnostics
lostridium
PCR
PCR
a  b  s  t  r  a  c  t
Background:  The  proximity  ligation  assay  (PLA)  detects  proteins  via  their  interaction  with  pairs  of  prox-
imity  probes,  which  are  antibodies  coupled  to  noncomplementary  DNA  oligonucleotides.  The  binding  of
both proximity  probes  to  their  epitopes  on  the  target  protein  brings  the  oligonucleotides  together,  allow-
ing them  to be  bridged  by a third  oligonucleotide  with  complementarity  to the other  two.  This  enables
their  ligation  and  the detection  of  the  resulting  amplicon  by real-time  quantitative  PCR  (qPCR),  which
acts  as  a  surrogate  marker  for the  protein  of interest.  Hence  PLA  has  potential  as  a clinically  relevant
diagnostic  tool  for the detection  of  pathogens  where  nucleic  acid  based  tests  are  inconclusive  proof  of
infection.
Methods:  We prepared  monoclonal  and  polyclonal  proximity  probes  targeting  Clostridium  difﬁcile  toxins
A (TcdA)  and  B (TcdB)  and  used  hydrolysis  probe-based  qPCR  and  digital  PCR (dPCR)  assays  to  detect
antibody/antigen  interactions.
Results:  The  performance  of  the  PLA  assays  was  antibody-dependent  but both  TcdA  and  TcdB  assays
were  more  sensitive  than comparable  ELISAs  in  either  single-  or dualplex  formats.  Both  PLAs  could  be
performed  using  single  monoclonal  antibodies  coupled  to different  oligonucleotides.  Finally,  we  used
dPCR  to demonstrate  its potential  for accurate  and  reliable  quantiﬁcation  of  TcdA.
Conclusions:  PLA  with  either  qPCR  or dPCR  readout  have  potential  as new  diagnostic  applications  for
the  detection  of pathogens  where  nucleic  acid based  tests  do  not  indicate  viability  or expression  of
toxins.  Importantly,  since  it is not  always  necessary  to use two  different  antibodies,  the  pool  of  potential
antibodies  useful  for  PLA  diagnostic  assays  is usefully  enhanced.
© 2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC. Introduction
The proximity ligation assay (PLA) [1] combines the speciﬁcity of
ntibody-based detection of proteins with the exquisite sensitivity
nd dynamic range of real time quantitative PCR (qPCR) to detect
ntigens in body ﬂuids and tissue samples [2]. Two antibodies cou-
led to non-complementary oligonucleotides are incubated with a
ample and in the presence of target protein the oligonucleotides
ome into close proximity in solution. A third oligonucleotide
omplementary to the 3′-end of one and the 5′-end of the other
ntibody-linked oligonucleotides anneals to both and facilitates a
igation event between the two oligonucleotides. This generates a
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214-7535/© 2016 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ligation product that can be detected by various methods includ-
ing qPCR (Fig. 1A). PLA offers several advantages over traditional
ELISAs, including better sensitivity, a broader dynamic range, sim-
pler workﬂow and faster time to results [3]. A proof of principle for
the detection of bacterial proteins has shown PLA to be as sensitive
as nucleic acid-based assays [4], although to-date there has been
only one report describing its use to detect a pathogen [5].
The spore-forming gram-positive bacillus Clostridium difﬁcile is
the cause of C. difﬁcile-associated infection (CDI) in hospital patients
[6] and has become the most common health care-associated
pathogen [7]. Elevated levels of two  key virulence factors, toxins
A (TcdA) and B (TcdB) [8] are associated with a sharp increase in
fatalities [9,10]. There are non-pathogenic C. difﬁcile strains that do
not express either toxin [11] and remain asymptomatic in more
than one-half of infected patients [12]. Such symptomless C. dif-
ﬁcile colonisation is associated with a decreased risk of CDI [13] .
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. PLAs targeting puriﬁed C. difﬁcile toxins using single mAbs. (A) The PLA
principle using a single mAb  is shown schematically. Following biotinylation and
a  successful forced proximity test, the mAb  is split into two  pools and one is cou-
pled to the 5′-, the other to the 3′-oligonucleotide. The pools are mixed with antigen,
ligated and analysed by qPCR. (B, biotin, S, streptavidin). (B) The difference in quan-
tiﬁcation cycle (Cq) obtained at each concentration compared to the “no protein
control” is plotted at each of seven antigen concentrations (250, 25, 2.5, 1.25, 0.625,
0.31 and 0.12 ng/mL). The dark boxes show the results from ﬁve independent PLAs
with the -TcdA mAb  coupled to either 5′- or 3′ oligonucleotide (Am5m3). The ﬂu-
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wrescent signal was detected using either duplicate (one PLA) or ﬁve replicate qPCR
eactions. The light boxes show the results from a PLA carried out in duplicate with
he  -TcdB mAb  (Bm5m3). Error bars show standard deviations.
ence PCR detection of asymptomatic C. difﬁcile colonisation may
e contributing to rising CDI rates by reporting a signiﬁcant num-
er of false positives [14] and may  result in unnecessary treatment
or many patients.
We  report the development of a hydrolysis probe-based PLA
ssay [15] to detect both C. difﬁcile toxins. We  have adapted the
ssay for accurate quantiﬁcation of bacterial proteins by digital PLA.
he assays can be performed using single mAbs, take 1.5 h to com-
lete, are more sensitive than traditional ELISAs and have a dynamic
ange of ﬁve orders of magnitude.
. Materials and methods
.1. Equipment
All pipetting steps were carried out using Biohit micropipettes
Sartorius Ltd, Epsom, UK). ELISA results were read on an iMarkTMicroplate Absorbance Reader (160-1130, BioRad, Hemel Hemp-
tead, UK). Centrifugation steps were carried out using a Rotina
80R centrifuge (Hettich Zentrifuge, Germany) for 96 well or 48
ell plates or a 5424 microfuge (Eppendorf, Stevenage UK) for and Quantiﬁcation 10 (2016) 2–8 3
microfuge tubes. qPCR assays were carried out using either a Biorad
CFX Connect (Biorad, Hemel Hempstead, UK) or a Eco48 (PCRMax,
Stone, UK). PCR reactions for digital PCR were carried out on a
TC9639 ﬂatbed thermal cycler (Denville Scientiﬁc Inc. South Plain-
ﬁeld, USA) before detection of amplicons on a Constellation dPCR
instrument (Formulatrix, Bedford, MA,  USA).
2.2. Antigens and antibodies
Puriﬁed and lyophilised C. difﬁcile TcdA and TcdB (CDA-TNL
and CDB-TNL, The Native Antigen Company, Upper Heyford, UK)
were reconstituted in 250 l of sterile distilled water (10245203,
Thermo Scientiﬁc, Loughborough, UK), giving ﬁnal concentrations
of 0.4 g/l and 0.2 g/l  of antigen, respectively, 0.05 M Hepes,
0.15 NaCl and 5% sucrose. Ten aliquots of antigen (25 l each) were
stored at 4 ◦C.
Protein G-puriﬁed mouse monoclonal anti-C. difﬁcile TcdA anti-
body (ab19953, Abcam, Cambridge, UK) was  raised against full
length protein and was  supplied at a concentration of 1.16 g/l
in 0.1% Sodium azide with 10 mM of PBS, pH7.2. It does not cross
react with TcdB.
Protein G-puriﬁed mouse monoclonal IgG1 anti-C. difﬁcile TcdB
antibody (ABIN234836, antibodies-online, Aachen, Germany) was
raised against full length protein and was supplied at a concentra-
tion of 1.14 g/l in 10 mM  PBS, pH7.4. It does not crossreact with
TcdA.
Chicken polyclonal IgY anti-C. difﬁcile TcdB antibody (PAB29154,
Abnova, Tapei, Taiwan) was  raised against native puriﬁed C. difﬁcile
toxin B with Freund’s adjuvant. It was  supplied at a concentration
of 2 g/l in 0.075% Sodium azide with 10 mM of PBS, pH7.2.
2.3. ELISA
TcdA and TcdB antigen concentrations were assayed in the range
of 1.25, 0.625 and 0.312 ng/mL and 2.5, 1.25, 0.625 ng/mL respec-
tively to determine the sensitivity of using a commercial sandwich
ELISA (TGC-E001-1, tgcBiomics, Bingen, Germany) as per manufac-
turer’s instructions. The ELISA was performed using the commercial
TcdA and TcdB antigens diluted in buffer supplied with the kit and
also in a suspension of canine faeces. Canine faeces was chosen as
a model as it simpliﬁed ethics considerations.
2.4. Biotinylation of antibodies
Biotinylation of the three antibodies was performed using
EZ-Link Sulfo-NHS-LC-Biotin, No-Weigh Format Biotinylation kit
(21327, Thermo Scientiﬁc, Loughborough, UK). 50 g of antibody
was added to 1 x PBS, pH7.4 (10051163, Thermo Scientiﬁc, Lough-
borough, UK) making a ﬁnal volume of 200 l to which 0.67 l of
10 nM biotin was added. Tubes were centrifuged at 10,000g for
10 s and incubated at 20 ◦C for 1 h. Two  × 100 l of each antibody-
biotin solution were transferred to two  Slide A- Lyzer mini dialysis
units (69562, Thermo Scientiﬁc, Loughborough, UK) per antibody
and free biotin was removed by dialysis in 1 L of 1x PBS, pH 7.4 at
4 ◦C. The buffer was  changed after 2 h, then twice after one hour
intervals, with a ﬁnal overnight dialysis against 2 L of buffer.
2.5. Forced proximity probe preparation and test
In a PLA, the term proximity probe refers to the anti-
body/oligonucleotide conjugate, ie there are two  proximity probes
per PLA, one with the 5′-oligonucleotide, the other with the 3′-
oligonucleotide. The forced proximity test helps to assess the
quality of biotinylated antibodies by determining whether or not
they can bind to the two oligonucleotides, which are streptavidin-
linked. Following biotinylation, individual antibodies are incubated
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ith both 5′- and 3′-oligonucleotides, resulting in both oligonu-
leotides binding to the same antibody. A ligation is carried out,
hich should be highly efﬁcient since both oligonucleotides are
lose together and the resulting DNA templates are ampliﬁed by
CR. At the same time 5′- and 3′- oligonucleotides are incubated
ithout antibodies, ligated and subjected to PCR. This should be
n inefﬁcient process and the Cqs recorded in these reactions are
ue to background ligation events. The kit’s suppliers suggest that
 difference in quantiﬁcation cycle (Cq) of 8.5 or greater between
he two treatments indicates efﬁcient biotinylation of the anti-
odies. If they do not pass this test, i.e. the Cqs are less than
.5, either the biotinylation reaction was not sufﬁciently efﬁcient
nd antibodies are under-biotinylated or there still is free biotin in
he solution because the dialysis of the biotin-antibody conjugates
as inadequate. The forced proximity test was carried out exactly
s per manufacturer’s instructions using antibody dilution buffer
4453745, Life Technologies, Carlsbad, CA, USA), 3′ and 5′ Prox-
ligo (4448549, Life Technologies), assay dilution buffer (4448571,
ife Technologies), ligation solution (4448592, Life Technologies),
ast master mix  (4448616, Life Technologies) and universal PCR
ssay buffer (4448592, Life Technologies). The qPCR was  carried
ut on a Biorad CFX Connect with the following cycling conditions:
5 ◦C for 2 min, 40 cycles of 95 ◦C for 15 s, and 60 ◦C for 30 s. Biotiny-
ated proximity probes passing the quality threshold were diluted
sing an equal volume of antibody dilution buffer, aliquoted and
tored at −80 ◦C at a ﬁnal concentration of 0.125 g/l.
.6. Proximity probe preparation
Two proximity probes for each antibody were prepared by com-
ining 5 l of 200 nM biotinylated antibody with 5 l of 200 nM 3′
proximity probe A) or 5′ (proximity probe B) Prox-Oligo. Follow-
ng a 10 s spin at 10,000 g, the mixture was incubated at 20 ◦C for
0 min. Following the addition of 90 l of probe storage buffer, the
ixture was incubated for a further 30 min  at 20 ◦C. Ten aliquots of
0 l of proximity probes A and B were made and stored at −20 ◦C.
.7. qPCR-PLA
A proximity probe mix  was prepared fresh each time by com-
ining 2.5 l each of proximity probes A and B with 125 l probe
ilution buffer and placing the mixture on ice. For each PLA, 2 l of
his proximity probe mix  was placed in a single well of a standard
hite qPCR 96 well plate (Biorad, Hemel Hempstead, UK) followed
y 2 l of target antigen, which was appropriately diluted with
x serum dilution buffer (SDB II, 4483013, Life Technologies). No
rotein controls (NPC) consisted of 2 l of proximity probe mix
nd 2 l of 1x SDB II. The plate was sealed using an optically clear
eat seal with a PX1 PCR plate sealer (Biorad, Hemel Hempstead,
K), centrifuged at 780g for 2 min  (Rotina 380R Hettich Zentrifuge,
ermany) and incubated for 1 h at 20 ◦C. Following removal of the
eal, 16 l of ligation solution II (4483013 Life Technologies) was
dded to each well, the plate was sealed again, spun as before and
he ligation was performed on a CFX Connect qPCR instrument with
he following conditions: 18 ◦C for 15 min  (ligation) and 60 ◦C for
0 min  (ligase deactivation). Since the ligation solution also con-
ains proprietary primers and FAM-labelled hydrolysis probe with
 non-ﬂuorescent quencher, ROX as well as the Taq polymerase and
NTPs, qPCR was carried out immediately using the following con-
itions: 95 ◦C for 2 min  and 40 cycles of 95 ◦C for 5 s and 60 ◦C for
0 s.
Alternatively, the PLA assay was carried out as described, but
sing 48 well plates suitable for the Eco48 sealed with Eco-speciﬁc
dhesive optically clear seals (PCRMax, Stone, UK). Since the instru-
ent cannot be programmed to run at 18 ◦C, the plate was  placed
n a cooled water bath (Grant Instruments Ltd, Shepreth, UK) prior and Quantiﬁcation 10 (2016) 2–8
to the qPCR reaction. Cycling conditions were the same as before,
i.e. 95 ◦C for 2 min  and 40 cycles of 95 ◦C for 5 s and 60 ◦C for 10 s.
For PLAs carried out on antigen suspended in canine faeces
50 mg  of faeces were added to 450 l of 1x SDB II, the suspension
was vortexed for 1 min  and centrifuged at top speed in a microfuge
for 3 min. Supernatants were collected, spiked with 10 or 1 ng/mL of
toxin A, transferred to Slide A- Lyzer mini dialysis units and dialysed
against 1 L of 0.5 × TE Buffer (T11493, Molecular Probe, Eugene, OR,
USA) at 4 ◦C. The buffer was changed after two  hours and dialysis
was continued overnight against 1 L of buffer. A non-spiked sample
was also dialysed for use with the no protein control assay. After
dialysis samples were transferred to microfuge tubes, the 10 ng/mL
sample was diluted to 1 and 0.5 ng/mL, the 1 ng/mL sample was
diluted to 0.1 ng/mL in 1x SDB and used for PLAs.
2.8. qPCR analysis
qPCR data (Cq values) were recorded from both the Biorad CFX
and the Eco qPCR instruments. Those from the Biorad CFX were
acquired using the regression algorithm supplied with the instru-
ment’s software, those from the Eco48 were obtained using the
threshold method. For the forced proximity test the Cq values
were calculated for each biotinylated antibody: average Cq (neg-
ative controls)—average Cq (forced proximity probes). If the Cq
was at least 8.5, the biotinylated antibody was  considered suitable
for use in the PLA. For the PLA, results were recorded as aver-
age Cqs ± standard deviations. The NPC was used as a reference
background and its Cq value determined the non-target ligation
background noise of the assay. Three replicate PLAs were performed
for each sample and NPC.
2.9. PLA with dPCR readout
The PLA was performed as described above, except that after
the inactivation of the ligase the white 96 well plate was cen-
trifuged at 780g for 2 min  and placed on ice without carrying out
the qPCR step. The Formulatrix Constellation dPCR system uses a
special microplate that contains 96 input wells on the top surface
and 496 microﬂuidic chambers per input well on the bottom sur-
face. 10 l of each assay were transferred from single wells on the
white 96 well plate to single wells on the Formulatrix microplate.
The dPCR plate was  sealed with a rubber seal (3M 300LSE, For-
mulatrix, Bedford, MA,  USA) and placed in the priming drawer of
the dPCR machine. Priming takes 15 min  and involves pins pushing
from above on the plate seal over each well to force the liquid into
the channels. A roller from below then forces a sealing tape into the
connecting channels, thus isolating the individual partitions from
one another and dividing each sample into 496 identical partitions.
The microplate was then placed on a ﬂat block thermal cycler to
amplify any ligated DNA templates using the following conditions:
95 ◦C for 3 min, followed by 40 cycles of 95 ◦C for 10 s, 60 ◦C for 30 s.
Following endpoint PCR, the microplate was  placed on the imag-
ing station at the top of the Constellation instrument, which takes
imaging proﬁles of each well.
2.10. dPCR analysis
An imaging proﬁle is a collection of imaging settings that are
used to image the microplate and typically deﬁnes ROX  as a refer-
ence ﬁlter and FAM and HEX as the reporter dye ﬁlters. A suitable
threshold is set for the reference ﬁlter to allow the analysis software
to distinguish between partitions that contain an assay from those
that have not been properly primed. Similarly, suitable thresholds
are set for the reporter dye ﬁlters to determine which partitions
have successfully ampliﬁed.
tection and Quantiﬁcation 10 (2016) 2–8 5
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Fig. 2. Dualplex assay targeting TcdA and TcdB with Am5m3  and Bm5m3. The dif-
ference in quantiﬁcation cycle (Cq) obtained at each concentration compared to
the  “no protein control” is plotted. PLAs were carried out in duplicate using two
′ ′H.S. Dhillon et al. / Biomolecular De
Thresholds for each ﬁlter are set using a separate threshold
creen and delineate an average brightness value, below which
 partition will be interpreted as empty if applied to the refer-
nce ﬁlter or negative if applied to a reporter dye ﬁlter. Above that
hreshold a partition is interpreted as containing an assay or a pos-
tive ampliﬁcation result. The threshold is set using a histogram
mage, which shows the number of partitions with an average
rightness value from 0 (completely dark) to 255 (completely
right). Typically, the histogram will show a bimodal distribution.
An initial assessment with the “raw images” view used the ROX
n the master mix  to conﬁrm that all partitions were properly ﬁlled
ith reagents and provided a visual estimate of target concentra-
ion. The ROX histogram displays two peaks, a tiny one on the
eft representing empty partitions and a much bigger one on the
ight representing partitions that contain reagents. The threshold
as placed between the two peaks. The FAM histogram also dis-
lays two peaks: one represents partitions without target DNA, the
ther those containing PCR amplicons. The threshold was  placed
alfway between the two peaks and the software then counted the
umber of positive partitions and calculated the amount of target
NA. Threshold settings were validated by using the Auto Thresh-
ld facility, which conﬁrmed the manual placing of the thresholds
etween the various peaks.
Unlike some other dPCR instruments which typically have
housands of partitions, the Formulatrix microplate has only 496
ompartments per 96 well. This means that the instrument has a
elatively small dynamic range, and requires the user to determine
ample concentrations by qPCR ﬁrst to ensure that not all com-
artments contain templates. Typically, target concentrations that
ecord Cqs above 28 are sufﬁciently dilute to generate reliable dPCR
ounts.
. Results
.1. ELISA
The lowest concentration tested that the ELISA was  able to
etect was 1.25 ng/mL for both TcdA and TcdB using neat dilutions
f antigen. Suspension of antigens in canine faeces at the same con-
entrations did not substantially alter the results of the ELISA (Fig.
1).
.2. Forced proximity test
This test compares the ampliﬁcation results obtained with an
ntibody/oligonucleotide conjugate to those obtained with oligos
nly. A large Cq between the two suggests that the antibody
as been efﬁciently biotinylated and the manufacturer’s stipulate a
inimum Cq value of 8.5. Biotinylation of all antibodies was  suc-
essful, as they signiﬁcantly exceeded the forced proximity quality
hreshold, with the TcdA proximity probe recording a Cq of 13.14,
he monoclonal TcdB 15.97 and the TcdB polyclonal 10.91 (Fig. S2
nd Table S1).
.3. PLA with qPCR readout
.3.1. TcdA
PLAs using two pools of a single mAb  targeting C. difﬁcile
cdA conjugated separately to either the 5′ or 3′ oligonucleotides
Am5m3) resulted in a sensitive PLA, detecting puriﬁed TcdA down
o 0.12 ng/mL of toxin. The repeatability of the assay was assessed
y performing four additional independent repeats of the PLA assay,
ith ﬁve replicates of each concentration. When all the results are
ombined, the associated variability (±SD) shows that it is possible
o detect as little 0.12 ng/mL of TcdA, which is ﬁve to ten times more
ensitive than the ELISA (Fig. 1B, coloured boxes). When the PLA wasseparate pools of 3 oligonucleotide- and 5 oligonucleotide-mAb targeting TcdA
(Am5m3) and TcdB (Bm5m3). Error bars show standard deviations.
performed using antigens suspended in canine faeces, the assay
was less sensitive, but sensitivity was  partly restored by overnight
dialysis (Table S2).
3.3.2. TcdB
PLAs using two pools of a single mAb  targeting C. difﬁcile
TcdB conjugated separately to either the 5′ or 3′ oligonucleotides
(Bm5m3) resulted in a PLA showing similar sensitivity to the
assay targeting TcdA, with 0.12 ng/mL the lowest level of antigen
detectable (Fig. 1B, clear boxes). The performance of the mAb-based
PLA was  compared to that of a conventional PLA utilising a combi-
nation of the same anti-TcdB monoclonal and polyclonal antiserum.
An initial assessment showed that the 5′-oligonucleotide-
monoclonal/3′-oligonucleotide-polyclonal combination (Bm5p3)
gave a better result than the 3′-oligonucleotide-monoclonal/5′-
oligonucleotide-polyclonal combination (Bm3p5) (Fig. S3). PLAs
carried out using Bm5m3  or Bm5p3 performed very similarly, with
Bm5m3 slightly more sensitive (Fig. S4).
3.4. Dualplex PLA targeting TcdB and TcdA
Next, the two  mAb-based PLA assays were combined into a
dualplex test with assay conditions the same as for the individual
PLAs. Results were similar to the ones recorded with the singleplex
assays, with quantiﬁcation down to 1.25 ng/mL and detection at
0.12 ng/mL of TcdB, although the variability at each concentration
was less (Fig. 2).
3.5. PLA with dPCR readout
Three independent PLAs targeting TcdA were analysed by dPCR
in duplicate with two different concentrations of TcdA (0.6 and
0.3 ng/mL) and indicated that it is possible to obtain reliable quan-
tiﬁcation of the copy numbers of ligated proximity probes (Fig. 3).
A comparison between PLA results obtained using either qPCR or
dPCR at the lowest concentration of antigen tested showed that
the results generated by the two readout methods are similar, with
dPCR recording an average difference of 3.1 ± 1.4 copies compared
with 0.8 ± 0.5 Cqs for qPCR (Fig. 4). Coefﬁcients of variation were
44% and 70%, respectively.
6 H.S. Dhillon et al. / Biomolecular Detection
Fig. 3. PLA with dPCR readout targeting TcdA. (A) Each row of the screen image
(labelled 1–3) corresponds to an independent PLA, carried out in duplicate at 0.6
(a,b) and 0.3 (c,d) ng/mL of antigen and with the no protein control (NPC) (e,f). (B)
The  positive counts calculated by the Constellation software are shown in the graph,
with the horizontal bar showing the median count.
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big. 4. Comparison of PLA results obtained with qPCR and dPCR at the limits of detec-
ion. The difference in copies (dPCR) or copy numbers (qPCR) obtained by diluting
cdA to 0.1 ng/mL were compared to the no protein controls (NPC).
. Discussion
There are numerous molecular methods available for the molec-
lar analysis and diagnosis of pathogens. Two key technologies
n widespread use target nucleic acids using PCR-based methods
nd proteins using a range of antibody-based techniques. Both
pproaches have their distinct advantages and disadvantages: PCR
ssays are easier to develop, are generally more sensitive, but detec-
ion of DNA does not prove the presence of a viable, infectious
athogen and that of RNA provides no information about protein
unctionality. Antibody-based tests can give a result in less than
ve minutes (e.g. a lateral ﬂow device) and have a low target purity
equirement, but can be difﬁcult to develop and the quality of the
est depends on the quality of the antibody.
Immuno-PCR [16] and real-time immuno-qPCR (iqPCR) [17]
epresent the ﬁrst attempts to combine the advantages of the two
pproaches whilst overcoming the limitations associated with tra-
itional immunoassays. However, the sensitivity and speciﬁcity of
qPCR assays as originally developed are antibody-dependent and
o not necessarily exceed that of the conventional ELISA because
oth are reduced by nonspeciﬁc background signals [18] probably and Quantiﬁcation 10 (2016) 2–8
caused by cross-reactive binding of the single antibody to non-
target proteins [19]. Nonetheless, appropriately designed sandwich
formats can improve the sensitivity of iPCR to make them 1000
-fold or more sensitive than ELISAs [20]. However, the most lim-
iting aspect of iPCR are (i) that its workﬂow involves a multi-step
process that results in signiﬁcant hands-on time requirements and
introduces the potential for contamination and (ii) that there is an
enhanced consumption of reagents [21].
In contrast, PLA is a homogeneous assay that uses two inter-
acting proximity probes to generate a signal and has signiﬁcant
potential to improve the sensitivity of detection [1]. Indeed, PLA
has been used for a wide variety of applications that range from
detection of proteins in single cells [22], cancer biomarkers [23]
and prions [24] to proposals for its use with personalised medicine
[25]. However, apart from a report detailing the proof of principle
for the detection of bacteria, [4], there is only one other report of
its use to detect pathogenic Escherichia coli [5].
The emergence of hyper virulent strains of C. difﬁcile and the
increased rate of morbidity and mortality associated with CDI
world-wide [26] makes reliable local surveillance to detect and
control endemic and epidemic CDI critical for patient manage-
ment and infection control. However, enzyme immunoassays lack
an adequate combination of sensitivity, speciﬁcity, and timeliness
[27,28] and a recent comparison of C. difﬁcile-speciﬁc in-house and
commercial qPCR assays found that the former lacked speciﬁcity,
whereas the latter lacked sensitivity [29].
Our report details the development of a PLA-based test that tar-
gets the two main bacterial toxins responsible for the pathogenicity
associated with C. difﬁcile. TcdA has multiple epitopes at its C-
terminal end that are recognised by a single antibody [30]. Hence
we reasoned that a single mAb, coupled differentially to oligonu-
cleotides, might be able to perform a PLA whilst minimising
background noise. Our results show that it is indeed possible to
use this approach to develop a highly sensitive assay against this
bacterial toxin. However, since TcdB is generally thought to be the
key virulence determinant [31] and TcdA-negative, TcdB-positive
isolates appear to be on the increase [32], we also developed a
TcdB-speciﬁc PLA. Like TcdA, TcdB has several repeated motifs at
its C-terminal end [33], hence we  decided to see whether a single
mAb  might also work in a TcdB-speciﬁc PLA. The results show that
it is likely that any protein with multiple identical epitopes can be
targeted by single mAb-PLAs. This ﬁnding has important implica-
tions for the practical usefulness of the PLA, especially for pathogen
detection, since proteins expressed by many pathogens have such
repeated elements [34]. Dualplexing also worked, with the limi-
tation that the TaqMan Protein Assay kit currently does not allow
the use of two  different DNA reporter sequences and ﬂuorophores
to distinguish two targets. However, Fig. 2 shows that dualplexing
resulted in less variability and that having four sets of PLA proximity
probes does not affect the performance of the assay.
One of the advantages of ELISAs is that samples do not need
to be puriﬁed before analysis as they are generally not inhibited by
biological ﬂuids. This is conﬁrmed by our own results with antigen-
spiked faeces shown in Fig. S1, where the PLA did not work well.
This was  not unexpected since faeces are known to contain numer-
ous inhibitors of the PCR reaction. However, inhibition was  relieved
by dialysis and dilution, making it likely that methods can be devel-
oped to overcome faeces-related inhibition.
One of the potential drawbacks of the PLA is that the negative (no
protein) controls always generates a Cq due to background ligation
events between the two  proximity probes. Hence it is important
to shift the background to as high a Cqs as possible, for exam-
ple by diluting the PLA reaction after the proximity probe and
antigen interaction step [22]. When we  compared Cqs recorded
by PLAs subjected to ligation and ampliﬁcation with and without
dilution we did indeed obtain an increase in Cq (Table S3). In con-
tection
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rast, changing the antibody concentrations used for generating the
roximity probes did not affect any of the Cqs (not shown).
dPCR is increasingly seen as an alternative to qPCR as it pro-
ides more precision, may  be less sensitive to inhibitors [35] and
llows the determination of absolute copy numbers. PLA in combi-
ation with digital RT-PCR has been used to quantify proteins and
RNA from single mammalian cells and demonstrate that there is
 low correlation between the two macromolecules [36]. The For-
ulatrix dPCR instrument provides a simple platform with physical
artitions, rather than the alternative, more complex droplet-based
PCR system and results in an easy to understand readout. It is also
ot restricted to any one company’s reagents, has a small footprint
nd software that is easy to use. Its main limitation is its relatively
ow dynamic range due to the small number of partitions (currently
96) available for each dPCR reaction. We  decided to determine
he usefulness of a dPCR approach and transferred the qPCR-based
ssay to the digital platform. The need to use a PCR instrument able
o handle ﬂat-bottomed plates resulted in slight modiﬁcations to
he PCR protocol, but resulted in a very sensitive, rapid and repro-
ucible PLA allowing us to count individual ligation events without
he need for any standard curve. We suspect that the sensitivity
f the PLA is dependent upon the efﬁciency of the ligation event
hat is required to generate a template that can be ampliﬁed by
CR. Hence improvements to the sensitivity of the PLA will require
mprovements to the ligation efﬁciency and there is a need to target
hat aspect of the PLA.
In summary, we report the ﬁrst use of two  single mAbs in a
LA targeting toxins produced by the clinically important bacterial
athogen C. difﬁcile. Since the assay is as sensitive and possibly less
ariable if it contains four proximity probes, there is clear potential
or a dual- or even multiplex application. Results can be obtained
rom faecal samples, with maximum sensitivity currently requiring
 dialysis step. The inclusion of dialysis is of course not ideal for the
implicity of the assay and signiﬁcantly increases the time required
o complete the assay. However, the development of high-capacity
ntibody-binding magnetic beads together with a simple workﬂow
37] will streamline the process of selecting and enriching anti-
en/proximity probe complexes and minimize the co-puriﬁcation
f inhibitors of the PCR reaction. Finally, we have substituted qPCR
ith a dPCR and report that it works reliably, reproducibly and with
igh sensitivity.
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